| 641571-10-0 Basic information More.. |
Product Name: | Nilotinib | Synonyms: | Nilotinib;Benzamide, 4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-;Nilotinib(TINIBS );4-Methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-N-(5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl)benzamide;4-methyl-N-(3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)benzamide;Nilotinib & its intermediates;Nilotinib for research;Nilotinib(AMN 107) | CAS: | 641571-10-0 | MF: | C28H22F3N7O | MW: | 529.52 | EINECS: | 700-544-5 | Mol File: | 641571-10-0.mol | ![641571-10-0](/CAS/GIF/641571-10-0.gif) |
Use
Nilotinib, an orally active signal transduction inhibitor that selectively inhibits the tyrosine kinase Bcr-Abl, was discovered and developed by Norvartis and was launched for the treatment of chronic myeloid leukemia (CML) in patients with Philadelphia chromosome-positive (Ph+) disease who are resistant or intolerant to imatinib mesilate. Additional clinical trials are currently underway for the treatment of acute lymphoblastic leukemia (ALL) and gastrointestinal stromal tumors (GISTs).
- Nilotinib
-
- US $0.00 / Kg/Bag
- 2024-08-29
- CAS:641571-10-0
- Min. Order: 10g
- Purity: 99%min
- Supply Ability: 5000g
- Nilotinib
-
- US $3500.00 / ASSAYS
- 2024-08-29
- CAS:641571-10-0
- Min. Order: 500g/Bag
- Purity: 99%
- Supply Ability: 100KG
- Nilotinib
-
- US $0.00-0.00 / kg
- 2024-05-09
- CAS:641571-10-0
- Min. Order: 1kg
- Purity: 99%,single impurity<0.1
- Supply Ability: 1 ton
|
641571-10-0
Recommend Suppliers |
|